Viability of cancer cells (e.g., glioblastoma cells) can be reduced by administering mannose to the cancer cells; and applying an alternating electric field with a frequency between 100 and 500 kHz to the cancer cells. Susceptibility to treatment with an alternating electric field can be determined by measuring uptake of a PKM2 probe (e.g., [18F]DASA) before and after treatment with an alternating electric field. Notably, experiments show that the combination of mannose and the alternating electric field produces a synergistic anti-glioblastoma result.

The present invention relates to novel peptides derived from Actin-like protein 8 (ACTL8), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer.

The present invention relates to a kit for radiolabelling a targeting agent with gallium-68. The present invention also relates to the use of the kit for radiolabelling a targeting agent, and a method for radiolabelling a targeting agent with gallium-68 using the kit.

The present invention relates to a kit for radiolabelling a targeting agent with gallium-68. The present invention also relates to the use of the kit for radiolabelling a targeting agent, and a method for radiolabelling a targeting agent with gallium-68 using the kit.

The present invention relates to novel, selective, radiolabelled mGluR2 ligands which are useful for imaging and quantifying the metabotropic glutamate receptor mGluR2 in tissues, using positron-emission tomography (PET). The invention is also directed to compositions comprising such compounds, to processes for preparing such compounds and compositions, to the use of such compounds and compositions for imaging a tissue, cells or a mammal, in vitro or in vivo and to precursors of said compounds.

The one subject of the invention is the compounds of general formula (I), their isomers, their physiologically acceptable salts and/or Mn(II), Fe(II), Fe(III), Co(II) and Ni(II) complexes. The other subject of the invention is the application of the above compounds. The compounds of general formula (I): wherein —NRR.sub.1 group may refer to: a) —NRR.sub.1 with N atom in the ring means a ring of 4 to 7, that in certain cases may contain another heteroatom, and in specific cases the ring may be replaced with an aryl group (of 5 to 7 carbon atoms) substituted with —COOH, —OH, —OCH.sub.3, —NO.sub.2, —NH.sub.2, —NCS, —NHS-activated ester, aryl (of 5 to 7 carbon atoms), or nitro-, amino- or isothiocyanate group, or b) in the —NRR.sub.1 group R means a H atom, alkyl, aryl, nitroaryl, aminoaryl or isothiocyanate-aryl group (of 1 to 6 carbon atoms) and R.sub.4 is a H atom, alkyl (of 1 to 6 carbon atoms) or —(CH.sub.2).sub.n—COOH group, whereas n=1 to 10 integer, or c) —NRR.sub.1 group is one of the following groups: (formula II) whereas R.sub.2 is a H atom, carboxyl- or alkyl-carbonyl group (of 1 to 4 carbon atoms); (formula III) and R.sub.2 is a H atom or alkyl or aryl group (of 1 to 6 carbon atoms), and X means independently from one another H atom, —CH.sub.3, —COOH, —OH, —OCH.sub.3, alkoxy- (of 2 to 6 carbon atoms), —NO.sub.2, —NH.sub.2, —NCS, —NHS-activated ester, alkyl (of 2 to 12 carbon atoms) or aryl (of 5 to 7 carbon atoms) group, in certain cases the latter may be substituted with hydroxyl, hydroxyalkyl (of 1 to 6 carbon atoms), nitro, amino or isothiocyanate group. ##STR00001##

The present invention relates to a metal-organic framework composition, as well as constructs and methods thereof. In one particular example, the composition provides a platform having an emission signal in the deep red to near-infrared (NIR) region.

The present disclosure relates to nanoparticles and the uses thereof in medicine, in particular for the treatment of tumours.

The present invention relates to novel compounds that bind to the prostate-specific membrane antigen (PSMA)-binding and their use in the diagnosis and treatment of certain diseases where PSMA is upregulated.

Methods are provided for diagnosing, prognosing, and treating cancers expressing SSTR2, in particular cancers of the head and neck, such as skull base malignancies, head and neck cancers and brain cancers, such as nasopharyngeal cancer and olfactory neuroblastoma. Provided is a non-invasive imaging method, where an imaging agent is administered to an individual with a tumor; where said imaging agent is then quantified within the tumor using PET-CT imaging to provide an indirect measurement of somatostatin receptor expression and to serve as a prognostic biomarker and companion diagnostic biomarker for treatment stratification in sinonasal cancers. Also provided are methods to directly measure SSTR2 expression from biopsied tumors. These methods robustly identify which patients will have increased rates of survival based on indirect and/or direct measurements of the level of expression of somatostatin receptors in tumors. In some embodiments, prognostic power of the non-invasive imaging method can be further increased by utilizing immunohistochemical analysis of tumor biopsies. In some embodiments, the methods further comprise selecting a treatment regimen for the individual based on the analysis.